IDXX Company Profile and Key Details
NASDAQ : IDXX
IDEXX Laboratories
$555.67
-14.58-2.56%
At Close 4:00 PM55.58
B-ESG ScoreESG Rating
Price Chart
Stock Price Today
IDEXX Laboratories, Inc. (IDXX) stock declined over -2.56%, trading at $555.67 on NASDAQ, down from the previous close of $570.25. The stock opened at $561.81, fluctuating between $549.42 and $562.82 in the recent session.
Stock Snapshot
570.25
Prev. Close
43.83B
Market Cap
549.415
Day Low
40.92
P/E Ratio
13.58
EPS (TTM)
9.3
Cash Flow per Share
561.81
Open
78.88M
Number of Shares
562.82
Day High
98.89%
Free Float in %
17.87
Book Value
578.3K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 08, 2026 | 562.82 | 562.82 | 549.41 | 555.67 | 578.3K |
| Jul 07, 2026 | 571.97 | 577.15 | 563.35 | 570.25 | 606.94K |
| Jul 06, 2026 | 561.40 | 567.08 | 547.93 | 564.98 | 628.34K |
| Jul 02, 2026 | 543.71 | 559.91 | 538.87 | 557.80 | 813.38K |
| Jul 01, 2026 | 533.61 | 539.09 | 528.71 | 537.58 | 647.05K |
| Jun 30, 2026 | 535.93 | 535.93 | 518.55 | 526.44 | 762.95K |
| Jun 29, 2026 | 551.92 | 556.24 | 534.66 | 535.93 | 799.31K |
| Jun 26, 2026 | 554.09 | 561.15 | 547.19 | 551.50 | 1.24M |
| Jun 25, 2026 | 549.99 | 570.84 | 545.66 | 554.94 | 617.16K |
| Jun 24, 2026 | 542.57 | 560.92 | 539.30 | 549.16 | 618.26K |
| Jun 23, 2026 | 548.75 | 552.25 | 538.44 | 541.31 | 646.57K |
| Jun 22, 2026 | 555.92 | 562.74 | 540.99 | 545.73 | 625.92K |
| Jun 18, 2026 | 549.29 | 563.85 | 546.18 | 562.09 | 1.15M |
| Jun 17, 2026 | 567.36 | 573.00 | 543.89 | 546.09 | 599.69K |
| Jun 16, 2026 | 573.28 | 574.08 | 567.36 | 573.00 | 479.68K |
| Jun 15, 2026 | 565.17 | 572.10 | 565.07 | 570.00 | 556.76K |
| Jun 12, 2026 | 558.44 | 561.74 | 552.23 | 560.88 | 514.72K |
| Jun 11, 2026 | 553.31 | 567.10 | 549.98 | 557.91 | 602.5K |
| Jun 10, 2026 | 574.47 | 575.43 | 555.86 | 556.94 | 578.71K |
| Jun 09, 2026 | 563.55 | 581.47 | 559.08 | 578.89 | 431.22K |
Contact Details
About Company
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
Company Information
| Employees | 11000 |
| Beta | 1.54 |
| Sales or Revenue | $3.90B |
| 5Y Sales Change% | 0.73% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
Stock Peers
MEDP
-14.3-2.62%
Medpace Holdings, Inc.$531.99NTRA-6.88-2.45%
Natera, Inc.$274.39ILMN-3.95-2.06%
Illumina, Inc.$187.81ICLR-3.25-1.93%
ICON Public Limited Company$165.47GH-6.75-4.14%
Guardant Health, Inc.$156.17BLLN2.56+2.17%
BillionToOne, Inc.$120.60ILMNV1.75+1.66%
Illumina, Inc. Common Stock Ex-distribution When-Issued$107.00EXAS00
Exact Sciences Corporation$104.91TWST-1.65-1.81%
Twist Bioscience Corporation$89.38RDNT-2.24-3.30%
RadNet, Inc.$65.59Company Overview
IDEXX Laboratories, Inc. (NASDAQ:IDXX) closed at $555.67 USD, losing -$14.58 (-2.56%) from the previous close of $570.25. The stock is currently mid-range between its 52-week high and low $506.91 and $769.98. With a market capitalization of about $43.83 billion, IDEXX Laboratories, Inc. is classified as a large-cap and shows higher-than-market volatility (beta ~1.55). Key stats such as the average daily volume over the past year has been around 632.70 thousand shares, in line with its 52-week average. Headquartered in Westbrook, ME, IDEXX Laboratories, Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Jonathan J. Mazelsky, the company employs approximately 11,000 people and listed since June 21, 1991. IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services.
Technical Performance
Short-term trend indicators are mixed aligned (SMA20 2.83%, SMA50 -2.17%, SMA200 5.23%). The stock’s 14-day RSI is 52.5 (neutral), while the ATR of 18.41 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -14.19% below its high and over 85.52% above its low. Average 10-day trading volume of 690.90 thousand shares is slightly above the 3-month average of 626.87 thousand, indicating heightened recent market interest.
Valuation Metrics
IDEXX Laboratories, Inc. trades at a P/E ratio of 40.87, slightly above the S&P 500 average, with a price-to-sales ratio of 9.91 and a price-to-book ratio of 28.76 reflecting a rich premium to book value. The P/FCF stands at 40.82, also above market averages. Compared to sector medians, IDEXX Laboratories, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.
Dividend & Fair Value
IDEXX Laboratories, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $157.98. This means the shares are trading above this model’s fair value.
Earnings & Analyst Outlook
IDEXX Laboratories, Inc. generated EPS of $13.08 over the past year. Five-year average earnings growth is 14.28%. Wall Street analysts project EPS growth of 12.75% annually over the next five years. The latest quarter delivered EPS of $3.47. The next quarter is forecast at $3.43. Next year's EPS is expected at $11.93. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 4 Buy ratings, 7 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $850.00 to $600.00. The high target offers 52.97% upside. The low target suggests 7.98% downside. The mean target is $734.17. This offers 32.12% upside. IDEXX Laboratories, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 05, 2026, missed forecasts by 1.76%. The prior quarter beat by 5.12%. Over the last six quarters, Apple has recorded several small beats. These include 9.62% in February 03, 2025.
Shareholding & Insider Activity
IDEXX Laboratories, Inc. has 80.00 million shares outstanding. The public float is 79.12 million shares, elevated short interest at 4.06% of float. This equals 2.48 million shares. The short ratio is 4.68 days. Institutional investors hold 96.51% of the float. Insiders own 0.71%. AYERS JONATHAN W holds 135.55 thousand shares, MAZELSKY JONATHAN JAY has 83.61 thousand shares and MCKEON BRIAN P has 29.72 thousand shares. Over the past six months, insider transactions show net selling. They sold 7.64 thousand shares across 6 transactions.
Financial & Profitability Overview
On valuation metrics, IDEXX Laboratories trades at a P/E of 40.87, P/S of 9.91 and P/B of 28.76. The current ratio is 1.12 and quick ratio is 0.82. Operationally, the company’s inventory turnover is 4.41 and cash conversion cycle is 111.85 days. Debt-to-equity is 0.71, supported by a cash flow-to-debt ratio of 1.09.
Quarterly Financial Highlights
The company ended the quarter with $453.93M in cash and short-term investments, a total debt of $947.88M, and net debt of $493.95M. Total assets were $3.26B, with equity of $1.48B. Financials further reflected stability, with operating cash flow of $906.51M, free cash flow of $772.88M, and capital expenditures of - $133.63M.
Price Forecast & Outlook
Our AI price prediction model suggests that IDEXX Laboratories, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.24%, with price expected at $548.80 by July 22, 2026, within a range of $537.21 to $560.08 3-Month Outlook: Projected rise of 16.28%, reaching $646.14 by October 06, 2026, with a range of $641.15 to $652.15. 1-Year Outlook: Projected gain of 9.58%, with price at $608.92 by July 08, 2027, within a range of $582.23 to $631.08.
Key Takeaways
IDEXX Laboratories, Inc. (NASDAQ:IDXX) shares are flat 1.4% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows IDEXX Laboratories, Inc. trading at a premium to the broader market with a P/E of 40.87. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $572.14, suggesting 2.96% upside. Our AI forecast model points to short-term weakness (-1.24% over two weeks), a medium-term rise (16.28% over three months), and a longer-term gain (9.58% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current IDEXX Laboratories, Inc. (IDXX) stock price?
IDEXX Laboratories, Inc. (NASDAQ: IDXX) stock price is $555.67 in the last trading session. During the trading session, IDXX stock reached the peak price of $562.82 while $549.42 was the lowest point it dropped to. The percentage change in IDXX stock occurred in the recent session was -2.56% while the dollar amount for the price change in IDXX stock was - $14.58.
IDXX's industry and sector of operation?
The NASDAQ listed IDXX is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. IDEXX Laboratories, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of IDXX?
Ms. Sharon E. Underberg
Executive Vice President, Gen. Counsel, & Corporation Sec.
Mr. James F. Polewaczyk
Executive Vice President & Chief Commercial Officer
Mr. Brian P. McKeon
Executive Vice President & Chief Financial Officer
Dr. Nimrata Khatra Hunt P.E., Ph.D.
Executive Vice President of Strategy, Sector Devel. & Global Operations
Mr. John Hart
Senior Vice President of Global Operations
Mr. Jeffery D. Chadbourne
Senior Director of Accounting & Financial Reporting
Mr. Ken Grady
Senior Vice President & Chief Information Officer
Mr. Jonathan J. Mazelsky
Pres, Chief Executive Officer & Director
Dr. Martin Smith Ph.D.
Executive Vice President & Chief Technology Officer
Mr. Michael J. Lane
Executive Vice President and GM of Reference Laboratories & Information Technology
Executive Vice President, Gen. Counsel, & Corporation Sec.
Mr. James F. Polewaczyk
Executive Vice President & Chief Commercial Officer
Mr. Brian P. McKeon
Executive Vice President & Chief Financial Officer
Dr. Nimrata Khatra Hunt P.E., Ph.D.
Executive Vice President of Strategy, Sector Devel. & Global Operations
Mr. John Hart
Senior Vice President of Global Operations
Mr. Jeffery D. Chadbourne
Senior Director of Accounting & Financial Reporting
Mr. Ken Grady
Senior Vice President & Chief Information Officer
Mr. Jonathan J. Mazelsky
Pres, Chief Executive Officer & Director
Dr. Martin Smith Ph.D.
Executive Vice President & Chief Technology Officer
Mr. Michael J. Lane
Executive Vice President and GM of Reference Laboratories & Information Technology
How IDXX did perform over past 52-week?
IDXX's closing price is 9.62% higher than its 52-week low of $506.91 where as its distance from 52-week high of $769.98 is -27.83%.
How many employees does IDXX have?
Number of IDXX employees currently stands at 11,000.
Link for IDXX official website?
Official Website of IDXX is: https://www.idexx.com
How do I contact IDXX?
IDXX could be contacted at phone 207 556 0300 and can also be accessed through its website. IDXX operates from One IDEXX Drive, Westbrook, ME 04092, United States.
How many shares of IDXX are traded daily?
IDXX stock volume for the day was 578.3K shares. The average number of IDXX shares traded daily for last 3 months was 632.7K.
What is the market cap of IDXX currently?
The market value of IDXX currently stands at $43.83B with its latest stock price at $555.67 and 78.88M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep